Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Taiho Oncology: Clinical Trials & FDA Approval Profile

Taiho Oncology (Global / Institutional) sponsors 16 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 9 active protocols (5 recruiting now), 3 completed protocols, and 3 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)25.0%
Median Closed Enrollment vs National (145 pts)108 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Taiho Oncology
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)16
Active Pipeline (Recruiting Now)9 (5)
Completed vs Stopped Early3 / 4 (25.0%)
Median Closed Actual Enrollment108 participants
Physical Hospital Site Disclosure97.4% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals3 (2 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Taiho Oncology
Hospital Research SiteLocationShared Protocols
MD Anderson Cancer CenterHouston, TX8
Hospital Universitario 12 de OctubreMadrid7
Vanderbilt University Medical CenterNashville, TN5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Taiho Oncology
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04256317A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND StPhase II/IIIRECRUITING
NCT05967689A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 InsertionsPhase IIRECRUITING
NCT05727176Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or RearrangementPhase IIRECRUITING
NCT07128199A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete TumorPhase IIIRECRUITING
NCT05973773REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)Phase IIIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Taiho Oncology Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI